SCOPUS 정보 검색 플랫폼

The Lancet

Volumn 383, Issue 9927, 2014, Pages 1442-1443

Antiretroviral dose reduction: Good for patients and rollout

(2) Lundgren, Jens D a Phillips, Andrew b

a UNIVERSITY OF COPENHAGEN (Denmark)

b UNIVERSITY COLLEGE LONDON (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOCHROME P450; DOLUTEGRAVIR; EFAVIRENZ; INTEGRASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; BODY DISTRIBUTION; BODY MASS; CENTRAL NERVOUS SYSTEM DISEASE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG TOLERABILITY; ETHNIC GROUP; FOLLOW UP; GENETIC VARIABILITY; HEALTH CARE COST; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL ASSESSMENT; MEDICATION COMPLIANCE; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; TUBERCULOSIS; VIRUS LOAD; WORLD HEALTH ORGANIZATION; TABLET; VOLUME OF DISTRIBUTION;

ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84899629480 PISSN: 01406736 EISSN: 1474547X Source Type: Journal
DOI: 10.1016/S0140-6736(13)62556-8 Document Type: Note

Times cited : (2)

References (9)

1
- 79551672781
- Geneva: Joint United Nations Programme on HIV/AIDS Jan 21
- UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS, 2013. http://www.unaids.org/ en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/ UNAIDS-Global-Report-2013-en.pdf (Jan 21, 2014).
- (2013) Global Report: UNAIDS Report on the Global AIDS Epidemic 2013

2
- 84882279538
- WHO Geneva: World Health Organization
- WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization, 2013.
- (2013) Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach

3
- 84899620845
- Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial
- ENCORE1 Study Group published online Feb 10
- ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014; published online Feb 10. http://dx.doi.org/10.1016/S0140-6736(13)62187-X.
- (2014) Lancet

4
- 84899656135
- A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz in combination with open label zidovudine with lamivudine at 36 weeks
- Geneva, Switzerland; June 28-July 3
- Haas D, Hicks C, Seekins D., et al A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz in combination with open label zidovudine with lamivudine at 36 weeks. International Conference on AIDS 1998; Geneva, Switzerland; June 28-July 3, 2008. 698.
- (2008) International Conference on AIDS 1998 , pp. 698
- Haas, D.¹ Hicks, C.² Seekins, D.³

5
- 79955073198
- Médecins Sans Frontières 16th edition, July Geneva: Médecins Sans Frontières, 2013 (accessed Jan 21, 2014)
- Médecins Sans Frontières. Untangling the web of antiretroviral price reduction-16th edition, July 2013. Geneva: Médecins Sans Frontières, 2013. http://d2pd3b5abq75bb.cloudfront.net/2013/09/11/ 10/25/44/896/MSF-Access-UTW-16th-Edition-2013.pdf (accessed Jan 21, 2014).
- (2013) Untangling the Web of Antiretroviral Price Reduction

6
- 84888856719
- Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ? 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials
- Molina JM, Clumeck N, Orkin C., et al Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ? 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Med 2014; 15: 57-62.
- (2014) HIV Med , vol.15 , pp. 57-62
- Molina, J.M.¹ Clumeck, N.² Orkin, C.³

7
- 84887052771
- Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection
- Warmsley SL, Antela A, Clumeck N., et al Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.
- (2013) N Engl J Med , vol.369 , pp. 1807-1818
- Warmsley, S.L.¹ Antela, A.² Clumeck, N.³

8
- 78249258110
- Dose optimisation: A strategy to improve tolerability and lower antiretroviral drug prices in low and middle-income countries
- Hill A, Ananworanich J, Calmy A. Dose optimisation: a strategy to improve tolerability and lower antiretroviral drug prices in low and middle-income countries. Open Infect Dis J 2010; 4: 85-91.
- (2010) Open Infect Dis J , vol.4 , pp. 85-91
- Hill, A.¹ Ananworanich, J.² Calmy, A.³

9
- 84860782217
- Low dose stavudine trials: A public health priority for developing countries
- Venter WDF, Innes S, Cotton M. Low dose stavudine trials: a public health priority for developing countries. S Afr J HIV Med 2012; 1: 20-21.
- (2012) S Afr J HIV Med , vol.1 , pp. 20-21
- Venter, W.D.F.¹ Innes, S.² Cotton, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.